Adjuvant Nivolumab as Standard of Care in Resected Bladder Cancer

Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.
Medscape Medical News